Rheumatoid arthritis

News

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moder

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

Partnership-Research-webinar-Images-16x9

Navigating new frontiers: Ways to find space in the future R...

Overview

News

Acute pain in a woman hand. Isolation on a white background

Galapagos shares surge on RA drug trial results

Shares in the Belgian biotech Galapagos have surged after a late stage trial of filgotinib, a rheumatoid arthritis drug it is developing with Gilead, met all its endpoints.

News

Biosimilars underused in rheumatoid arthritis on the NHS - e...

Experts call for lower disease activity threshold for biologic drugs

News

Celltrion hopes to outdo inflammatory disease rivals with SC...

Drugmaker could file in EU in coming weeks, according to report

News

More good news for AbbVie in rheumatoid arthritis

AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

Navigating new frontiers: Ways to find space in the future R...

Galapagos shares surge on RA drug trial results

Biosimilars underused in rheumatoid arthritis on the NHS - e...

Celltrion hopes to outdo inflammatory disease rivals with SC...

More good news for AbbVie in rheumatoid arthritis

Setback for MSD as German court blocks Keytruda SC launch

How to meet your physicians where they are online

Rheumatoid arthritis

Editor's Picks